Skip to main content
Clinical Trials/NL-OMON47431
NL-OMON47431
Completed
Phase 4

REMission INDuction in very early Rheumatoid Arthritis - REMINDRA

niversitair Medisch Centrum Utrecht0 sites267 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Arthritis
Sponsor
niversitair Medisch Centrum Utrecht
Enrollment
267
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Eligibility Criteria

Inclusion Criteria

  • To be eligible to participate in this study, a subject must meet all of the following criteria:
  • \- Able and willing to give written informed consent
  • \- At least 18 years of age
  • \- Fulfilling 2010 ACR/EULAR criteria for RA (Appendix A.)
  • \- Patient reported symptom duration (joint stiffness, tenderness, pain, and/or swelling) \< 12 months
  • \- Naïve for DMARD and biological treatment
  • \- DAS28 \<\=\>3\.2
  • \- Have sufficient knowledge of the Dutch language to be able to comply with the requirements of the study protocol

Exclusion Criteria

  • A potential subject who meets any of the following criteria will be excluded from participation in this study:
  • \- Having used glucocorticoids \< 6 weeks before the baseline visit
  • \- Being pregnant (based on anamnesis) or a nursing women or a women of child bearing potential without (adequate) use of contraception
  • \- Having any other inflammatory rheumatic disease than RA, except for secondary Sjögren\*s syndrome
  • \- Having contraindications for the use of MTX/HCQ/methylprednisolone/GOL.

Outcomes

Primary Outcomes

Not specified

Similar Trials